Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
By S. Richardson, J. Hirsch, M. Narasimhan, J. Crawford, T. McGinn, Karina W. Davidson, D. Barnaby, L. Becker, J. Chelico, S. Cohen and 17 more. Journal of the American Medical Association (JAMA), 2020
8,662 citations recorded by the source corpus.
Importance There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19). Objective To describe the clinical characteristics and outcomes of patients with COVID-19 hospitalized in a US health care system. Design, Setting, and Participants Case series of patients with COVID-19 admitted to 12 hospitals in New York City, Long Island, and Westchester County, New York, within the Northwell Health system. The study included all sequentially hospitalized patients between March 1, 2020, and April 4, 2020, inclusive of these dates. Exposures Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive result on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring admission. Main Outcomes and Measures Clinical outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement therapy, and death. Demographics, baseline comorbidities, presenting vital signs, and test results were also collected. Results A total of 5700 patients were included (median age, 63 years [interquartile range {IQR}, 52-75; range, 0-107 years]; 39.7% female). The most common comorbidities were hypertension (3026; 56.6%), obesity (1737; 41.7%), and diabetes (1808; 33.8%). At triage, 30.7% of patients were febrile, 17.3% had a respiratory rate greater than 24 breaths/minute, and 27.8% received supplemental oxygen. The rate of respiratory virus co-infection was 2.1%. Outcomes were assessed for 2634 patients who were discharged or had died at the study end point. During hospitalization, 373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. Mortality for those requiring mechanical ventilation was 88.1%. The median postdischarge follow-up time was 4.4 days (IQR, 2.2-9.3). A total of 45 patients (2.2%) were readmitted during the study period. The median time to readmission was 3 days (IQR, 1.0-4.5) for readmitted patients. Among the 3066 patients who remained hospitalized at the final study follow-up date (median age, 65 years [IQR, 54-75]), the median follow-up at time of censoring was 4.5 days (IQR, 2.4-8.1). Conclusions and Relevance This case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area.
Subfields: Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/dd86b3551add27004b5bf3f5fb206bec9cd69c4f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Neurology
Citations in the corpus
- Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 (2020, neutral): “Age and comorbidities (including obesity, diabetes mellitus, cardiovascular and respiratory diseases, and cancer) are predictors of severe COVID-19 disease (Richardson et al., 2020).”
- Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19 (2020, neutral): “This group of patients holds particular interest for this study, as early intervention could substantially reduce progression to hypoxic respiratory failure requiring mechanical ventilation, a clinical event associated with mortality rates estimated as high as 67%–94% [2–4].”
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 (2020, background): “4: Hospitalized, requiring low-flow supplemental oxygen 19 (10) 14 (7)”
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity (2020, positive): “…increased rates of severe and fatal disease among older individuals (> 65 years old) (Docherty et al., 2020; Grasselli et al., 2020) and those with pre-existing medical conditions like cardiovascular disease, obesity, and type 2 diabetes mellitus (Docherty et al., 2020; Richardson et al., 2020).”